Eagle Pharmaceuticals and Spectrum Pharmaceuticals Announce Co-Promotion Agreement

On November 4, 2015 Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") and Spectrum Pharmaceuticals (NASDAQ:SPPI) ("Spectrum") reported that they have entered into a co-promotion agreement ("the agreement") under which the Spectrum 32-person Corporate Accounts Sales Team will dedicate 80 percent of its time to selling and marketing up to six Eagle products over a period of at least 18 months (Press release, Spectrum Pharmaceuticals, NOV 4, 2015, View Source [SID:1234507976]). Spectrum will continue to maintain a separate sales force to market existing and potential hematology products.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement leverages the experience and network of the Spectrum Corporate Accounts Sales Team in order to maximize the respective product sales of both companies by targeting infusion centers, hospitals, and oncology purchasing groups.

The Spectrum Corporate Accounts Sales Team is a group of 32 proven and seasoned professionals focused in the hematology and oncology space, calling on infusion centers and hospitals. Each team member has extensive pharmaceutical industry experience, including years of oncology-specific experience. This cohesive team has demonstrated strong performance and they are poised to commercialize Eagle’s promising assets.

Under the terms of the agreement, the Spectrum Corporate Accounts Sales Team will promote up to six products. This will potentially include Eagle’s current pipeline plus products that may be in-licensed over time. Eagle’s approximately 20 direct sales representatives will focus on promoting Eagle products with an initial emphasis on the launch of RTU Bivalirudin and RYANODEX (dantrolene sodium).

As outlined in the agreement, Eagle will pay Spectrum a base fee of $12.8 million over 18 months. Spectrum will also have the opportunity to earn an additional $9 million in specific identified sales milestone payments if its Corporate Accounts Sales Team surpasses sales projections, for a potential total payment of up to $22 million in base fee and specified milestones over 18 months. The agreement grants both companies the opportunity for six-month renewal periods upon mutual agreement.

"Our agreement with Spectrum is a very positive step at this exciting and critical time for Eagle as we transition from a development-stage pharmaceutical company to a commercial organization with a portfolio of differentiated, in-market products and a continued promising pipeline," said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals. "Driven by our commitment to building sustainable, long-term shareholder value, this agreement allows Eagle to make this transition with little commercial risk and minimal financial obligation while we deliberately build our own commercial sales team."

"By partnering with Spectrum, we are capitalizing on a unique opportunity to strategically secure a highly-successful sales team that will spend 80 percent of its time calling exclusively on Eagle’s customers, infusion centers, hospitals, and oncology purchasing groups. We are confident that Spectrum’s proven sales team will help Eagle maximize the success of new product launches and achieve our increased revenue goals while reducing the expense burden prior to and during the launch process," concluded Tarriff.

"Partnering with Eagle is a value-enhancing opportunity as we continue our efforts to bring innovative products for patients and enhance value for Spectrum shareholders," said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. "The timing of the agreement allows us to quickly leverage our existing infrastructure to launch and market Eagle’s drugs. Moreover, maintaining a cohesive and engaged sales team has long-term strategic value for Spectrum. By working with Eagle to promote its expanding portfolio of marketed products, we are providing the members of the Spectrum Corporate Accounts Sales Team an opportunity to strengthen their partnerships with key stakeholders in the oncology marketplace and participate in the engaging work of launching important therapeutics. We look forward to working closely with Eagle to bring improved specialty products to health care professionals and patients."

Eagle to Hire Approximately 20 Direct Sales Representatives as Part of Long-Term Commercialization Strategy; Sales Team to Form Company’s Internal Commercial Organization

As part of the co-promotion agreement and long-term strategy to build an internal commercial team, Eagle will also hire approximately 20 direct sales representatives who will be a part of Eagle’s independent commercial organization. These representatives will be managed under the Spectrum sales team infrastructure for the duration of the co-promotion agreement. This arrangement serves to ensure a well-trained sales team and facilitates a seamless, low-cost transition with minimal risk.

Eagle expects its in-market portfolio will significantly expand in 2016, assuming FDA approvals for Docetaxel Injection, RTU bivalirudin, and the tentatively approved 500 mL RTD bendamustine. Anticipated approval dates for these products are in December 2015, March 2016, and May 2016, respectively. Combined with anticipated royalties from Teva for rapidly administered bendamustine 50 mL, revenues from RYANODEX, and royalties from commercial partner net product sales for argatroban, the Company expects an increasing revenue stream and expedited ability to deliver long-term, sustainable growth.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results

On November 04, 2015 MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, reported a corporate progress update and reported financial results for the third quarter ended September 30, 2015 (Press release, MacroGenics, NOV 4, 2015, View Source [SID:1234507969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we strive to create breakthrough biologics and life-changing medicines, the team at MacroGenics was proud to share our progress at our recent R&D Day in New York," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "We reported encouraging initial clinical trial results from an ongoing Phase 1 study of enoblituzumab, our Fc-optimized monoclonal antibody that targets B7-H3. We also extended our B7-H3 franchise by advancing MGD009, a DART molecule directed against B7-H3 and CD3, into a Phase 1 study. Furthermore, we recently announced a collaboration with Merck to evaluate margetuximab in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, in patients with advanced gastric cancer. This combination of therapeutics could exploit complementary immune-based mechanisms for targeting tumors and provide an important alternative for patients who do not respond to currently available regimens."

Pipeline Update

Margetuximab is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2. Recent highlights include:

Phase 1b/2 Gastric Cancer Study in Collaboration with Merck: The Company recently announced a collaboration to evaluate the combination of margetuximab with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in a Phase 1b/2 clinical trial in patients with HER2-positive advanced gastric cancer. Trial startup activities are underway, and the Company expects to begin enrolling patients by the first quarter of 2016.

SOPHIA Study Continues: The Company’s Phase 3 pivotal study in patients with HER2-positive metastatic breast cancer is continuing enrollment. This three-year study is evaluating the efficacy of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy following progression after at least two lines of previous therapy in approximately 530 patients.
B7-H3 Franchise—MacroGenics is developing a portfolio of therapeutics that target B7-H3, a member of the B7 family of molecules involved in immune regulation. The Company’s three programs target B7-H3 through complementary mechanisms of action and take advantage of this target’s broad expression across multiple solid tumor types. Recent highlights include:

Enoblituzumab (MGA271): The Company provided an overview of initial data from its ongoing Phase 1 monotherapy clinical study of enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3. To date, enoblituzumab has been well tolerated in patients and has shown encouraging, initial single-agent activity, including tumor regression in multiple, heavily pre-treated patients. In addition, evidence of T-cell immunomodulatory function has been observed in patients treated with enoblituzumab. The Company continues to enroll patients in additional monotherapy Phase 1 study cohorts as well as in two combination studies with either ipilimumab or pembrolizumab. Data from the ongoing monotherapy study will be presented in a late-breaking abstract session at the 2015 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 7, 2015.

Regains European and Other Regional Rights to Enoblituzumab: In October 2015, Les Laboratoires Servier, or Servier, provided notice that it would not be exercising its option under a 2011 agreement to develop and commercialize enoblituzumab in Europe and other countries. Accordingly, the agreement with Servier regarding enoblituzumab has expired and MacroGenics now controls worldwide development and commercialization rights to enoblituzumab. The agreement between MacroGenics and Servier for development of DART molecules is unaffected by this decision.

MGD009 in Phase 1: MGD009, a Dual-Affinity Re-Targeting, or DART, molecule targeting B7-H3 and CD3, is being tested in a Phase 1 study in patients and is being evaluated across multiple solid tumor types.

B7-H3 Antibody-Drug Conjugate: The Company continues to evaluate antibody drug conjugate (ADC) molecules to induce direct killing of B7-H3 positive tumor cells.

DART Product Candidates—There are currently five DART molecules in clinical development, including MGD006 (CD123 x CD3, also known as S80880), MGD007 (gpA33 x CD3), MGD011 (CD19 x CD3, also known as JNJ-64052781), MGD010 (CD32B x CD79B) and MGD009 (B7-H3 x CD3). Each of these DART molecules is being evaluated in a Phase 1 clinical study. At its R&D Day, the Company disclosed for the first time two DART molecules that it expects to advance into clinical development in the first half of 2017. These two product candidates include:

MGD013: MacroGenics is developing an Fc-bearing DART molecule, MGD013, to simultaneously block two immune checkpoint molecules, PD-1 and LAG-3. The company presented promising pre-clinical data demonstrating the activity of a DART molecule with these specificities and expects that this bi-specific combination may be useful for treatment of a wide range of solid tumors and hematological malignancies. Beyond MGD013, MacroGenics is generating and evaluating multiple other candidates that target a range of immune regulatory molecules using its DART platform as well as its Trident platform for generating tri-specific molecules.
MGD014: MacroGenics presented pre-clinical data on MGD014, a DART molecule that is being developed to eliminate latent HIV infection. MGD014 will be developed under a contract recently awarded by the National Institute of Allergy and Infectious Diseases for up to $24.5 million. This is the first infectious disease DART program planned for clinical testing.

Corporate Update

Equity Offering: In July, the Company completed an equity offering, raising $141 million in net proceeds, which included exercise of the underwriters’ over-allotment option in full. MacroGenics is using the proceeds of this offering to expand its manufacturing capacity and accelerate development of immune regulatory-based product candidates, including MGD013, advance other research and development programs, in-license or acquire other products or technologies, and for general corporate purposes.

Partners’ DART Molecules Advance: As previously announced, MacroGenics’ collaboration partner, Janssen Biotech, Inc., paid the Company a $10 million milestone during the third quarter of 2015 after dosing a first patient in an open-label Phase 1 study of MGD011. Also, in October 2015, MacroGenics’ collaboration partner, Boehringer Ingelheim, selected a DART molecule for further pre-clinical development. This triggers a $5 million milestone payment to MacroGenics under an October 2010 agreement to discover, develop and commercialize DART therapeutics.

Manufacturing Expansion: During the third quarter, the Company signed a lease for additional space with a focus on expanding its commercial manufacturing capabilities.

Third Quarter 2015 Financial Results

Cash Position: Cash and cash equivalents as of September 30, 2015 were $365.8 million, compared to $157.6 million as of December 31, 2014. The Company expects that its cash balance should fund operations into 2018.

Revenue: Total revenues, consisting primarily of revenue from collaborative research, were $14.7 million for the three-month period ended September 30, 2015 compared to $18.4 million for the three-month period ended September 30, 2014. Collaborative research revenue includes the recognition of deferred revenue from payments received in previous periods as well as payments received during the quarter.

R&D Expenses: Research and development expenses were $24.1 million for the three-month period ended September 30, 2015, compared to $18.6 million for the three-month period ended September 30, 2014. This increase was primarily due to preparations for and launch of the margetuximab SOPHIA Phase 3 study, increased activity to prepare for the MGD009 Investigational New Drug (IND) application submission, and costs of other ongoing clinical studies.

G&A Expenses: General and administrative expenses were $6.0 million for the three-month period ended September 30, 2015, compared to $3.7 million for the three-month period ended September 30, 2014. This increase was primarily due to higher labor-related costs, including stock-based compensation expense and information technology-related expenses.

Net Loss: Net loss was $15.4 million for the three-month period ended September 30, 2015, compared to net loss of $3.9 million for the three-month period ended September 30, 2014.

Shares Outstanding: Shares outstanding as of September 30, 2015 were 34,248,240.

Third Quarter 2015 Report

On November 4, 2015 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported its revenues and cash position for the first nine months of 2015 (Press release, Innate Pharma, NOV 4, 2015, View Source [SID:1234507967]). Cash, cash equivalents and financial instruments of the Company amounted to €269.6 million at September 30, 2015. At the same date, its financial liabilities amounted to €3.9 million (lease-financing of its premises).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Revenues for the first nine months of 2015 amounted to €13.1 million (€1.0 million for the same period in 2014).

This revenue results from Innate Pharma’s collaboration and licensing agreement with Bristol-Myers Squibb and co-development and commercialization agreement with AstraZeneca:

€5.5 million from the agreement with Bristol-Myers Squibb including a €4.4 million milestone payment as well as €0.7 million from the recognition over the period of the upfront payment received in July 2011;
€7.6 million resulting from the agreement with AstraZeneca, corresponding to the recognition over the period of the initial payment received in April 2015.

Revenue for the first nine months of 2014 mainly resulted from the recognition over the period of the upfront payment received in 2011 from Bristol-Myers Squibb (€0.6 million).

Business update:

During the period, clinical and research discovery activities moved forward as anticipated. Regarding Innate’s three most advanced programs:

Lirilumab: a first patient was dosed in the Phase II trial of lirilumab in combination with rituximab in patients with relapsed/refractory or high-risk untreated Chronic Lymphocytic Leukemia, triggering a milestone payment from Bristol-Myers Squibb;

IPH2201: a first patient was treated in the Phase I/II trial in ovarian cancer and the Phase I/II trial in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia started;

IPH4102: the rationale of the program and the Phase I design were presented at the cutaneous lymphoma task force meeting of the EORTC as well as during a KOL event organized in New-York. The enrolment of the first patient is expected in the coming weeks.

8-K – Current report

On November 4, 2015 Immunomedics, Inc. (Nasdaq:IMMU) reported financial results for the first quarter ended September 30, 2015. The Company also highlighted recent key developments and planned activities for its clinical pipeline (Filing, 8-K, Immunomedics, NOV 4, 2015, View Source [SID:1234507965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Quarter Fiscal 2016 Results

Total revenues for the first quarter of fiscal year 2016, which ended on September 30, 2015, were $0.7 million as compared to total revenues of $1.1 million for the same quarter last fiscal year. The decrease of $0.4 million in total revenues was primarily due to a $0.2 million reduction in research and development revenue from a decline in the number of government funded research grants and $0.1 million in reduced product sales due primarily to unfavorable currency rates on LeukoScan sales in Europe.

Total costs and expenses for the current quarter were $14.8 million as compared to $13.5 million for the same period in 2014, representing an increase of $1.3 million or 10%. This increase was driven primarily by $3.5 million higher research and development expenses for product development expenses related to the Phase 3 PANCRIT-1 registration study of yttrium-90-labeled clivatuzumab tetraxetan for the therapy of patients with advanced pancreatic cancer and the Phase 2 antibody-drug conjugates’ clinical trials. The increase in cost and expenses this quarter was partially offset by the $2.1 million decrease in general and administrative expenses attributable primarily to reduced legal and professional fees, principally related to the arbitration proceedings with Takeda-Nycomed, which concluded during the 2015 fiscal year.

Interest expense this quarter related to the 4.75% Convertible Senior Notes was $1.4 million, including the amortization of $0.2 million debt issuance costs. There was no interest expense for the same quarter last fiscal year.

Net loss attributable to our stockholders this quarter was $15.4 million, or $0.16 per share, compared with a net loss attributable to our stockholders of $12.4 million, or $0.13 per share, for the same quarter in fiscal 2015. The $3.0 million increase in net loss this quarter was primarily due to $3.5 million increased clinical trial-related research and development costs and $1.4 million interest expense, partially offset by $2.1 million decreased legal and professional fees, as described above.

As of September 30, 2015, cash, cash equivalents, and marketable securities totaled $85.5 million.

"As presented by Dr. Goldenberg at the 2015 World ADC conference in San Diego, sacituzumab govitecan continues to show consistently encouraging results in patients with metastatic solid cancers. We are continuing to progress our regulatory activities regarding a Phase 3 registration trial in TNBC," commented Peter P. Pfreundschuh, Vice President Finance and Chief Financial Officer. "In addition, patient enrollment for the PANCRIT-1 trial has significantly increased in the last quarter, and we are on track to complete patient accrual during calendar year 2016," added Mr. Pfreundschuh.

The Company’s key clinical developments and future planned activities:

Sacituzumab Govitecan (IMMU-132)

At the 2015 World ADC San Diego conference, sacituzumab govitecan was reported to have produced durable responses that exceeded one year in some patients with metastatic triple-negative breast (TNBC), small-cell (SCLC) and non-small-cell lung (NSCLC) cancers. (For more information on the results, please refer to the Company’s press release at View Source).

Interim results in patients with advanced, metastatic lung cancers were also presented at the 16th World Conference on Lung Cancer.
(View Source)

A late-breaking abstract focusing on results in patients with TNBC has been accepted for presentation at the 2015 AACR (Free AACR Whitepaper)-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, scheduled for Sunday, November 8, 2015, in Boston, Massachusetts.

Further update in TNBC will be provided in a poster discussion session at the 2015 San Antonio Breast Cancer Symposium in San Antonio, Texas, on Thursday, December 10, 2015.

Full updates on the sacituzumab govitecan Phase 2 study will be given at the Cambridge Healthtech Institute’s 15th Annual PepTalk: The Protein Science Week in San Diego, California, scheduled for Wednesday, January 20, 2016.
IMMU-114

Initial results of a Phase 1 first-in-man study of subcutaneous injections of IMMU-114 in hematologic malignancies will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in Orlando, Florida, on Sunday, December 6, 2015.

Roche showcases pharmaceuticals strategy and emerging new medicines

On November 5, 2015 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported that it is providing an update on its late-stage pipeline at an investor event in London, including promising investigational medicines for multiple sclerosis, asthma, haemophilia, eye disease and cancer (Press release, Hoffmann-La Roche , NOV 4, 2015, View Source [SID:1234507963]). In these and other areas, Roche expects as many as seven major read-outs from clinical trials with new molecular entities or line extensions for existing medicines up to the end of 2017, adding to the seven read-outs already achieved in 2015.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Thanks to our diversified late-stage portfolio we are well positioned to maintain our leadership in oncology, expand further in the immunology and ophthalmology segments, and potentially offer new treatments to help improve the lives of people with multiple sclerosis and haemophilia," said Daniel O’Day, COO of Roche’s Pharmaceuticals Division. "And we are looking to harness the vast increase in molecular information as the next important step in our efforts to develop even better, more personalised treatment solutions."

In addition to presenting updates on Roche’s most advanced investigational medicines, executives will brief investors and analysts on the company’s strategy, R&D productivity, life-cycle management and approach to new market opportunities. Special breakout sessions will offer insights into Roche’s haematology portfolio, plans to exploit the growing depth and breadth of molecular information for drug discovery and development, and an assessment of the emerging biosimilar landscape.

The presentations will be available via live video webcast or conference call (details at the end of this release).

Addressing unmet need in melanoma, lung cancer and multiple sclerosis

Cotellic is currently undergoing regulatory review in the US and Europe for use in combination with Zelboraf for the treatment of BRAF mutation-positive unresectable metastatic melanoma. Decisions by the FDA and EMA are expected in November and December, respectively. Results from a phase III trial announced by Roche and Exelixis in October showed a statistically significant and clinically meaningful increase in overall survival for patients taking Cotellic plus Zelboraf compared to Zelboraf alone.
Alectinib is an investigational oral medicine for ALK-positive non-small cell lung cancer (NSCLC). After granting Breakthrough Therapy Designation in 2013, the FDA accepted Roche’s US marketing application in September 2015 for priority review, assigning a decision date in March 2016. Roche also filed an EU marketing application in September. A phase III study is comparing alectinib to crizotinib as initial treatment for advanced NSCLC identified as ALK-positive by a companion diagnostic test being developed by Roche.

Ocrelizumab is the first investigational medicine to show positive results in both primary progressive and relapsing forms of multiple sclerosis (PPMS, RMS). Based on pivotal study results, ocrelizumab has the potential to change the way MS is treated. Roche plans to submit data to global regulatory authorities in early 2016 to obtain marketing authorisation for ocrelizumab as a potential new treatment for RMS and first approved treatment for PPMS.

Cancer immunotherapy – preparing a multipronged attack on tumours

Roche’s industry-leading cancer immunotherapy pipeline currently includes eight new molecular entities and some 30 combinations of immunotherapies and targeted cancer medicines being tested in clinical trials.

Atezolizumab is an investigational monoclonal antibody designed to interfere with PD-L1, a protein expressed on tumour cells and tumour-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on the surface of T cells. By inhibiting PD-L1, atezolizumab may enable the activation of T cells, restoring their ability to detect and attack tumour cells. Roche has initiated a rolling FDA filing for atezolizumab and expects to finalise the data submissions from its phase II trials in the first quarter of 2016 under Breakthrough Therapy Designations for certain types of metastatic bladder and lung cancer. Roche currently has several ongoing phase III studies of atezolizumab alone or in combination with other medicines for various types of lung, bladder, kidney and breast cancer. All studies include the evaluation of a companion test developed by Roche Diagnostics to determine PD-L1 status.

Atezolizumab plus chemotherapy: Based on encouraging early-stage results, Roche is conducting a number of randomised phase III studies to evaluate the benefit of atezolizumab when added to standard chemotherapy in first-line NSCLC. First results are expected in 2017.

Atezolizumab combined with targeted therapies or other cancer immunotherapy agents: Roche is also investigating the potential benefit of combining atezolizumab with targeted medicines such as Avastin, Zelboraf, Cotellic, Tarceva, alectinib or Gazyva, as well as with other cancer immunotherapy agents such as anti-CD40, anti-CSF-1R, anti-OX40, IDO inhibitors or anti-CEA-IL2v FP in a range of cancers.

Aiming for treatment advances for blood cancers, asthma, haemophilia and age-related vision loss

Gazyva/Gazyvaro (obinutuzumab), a glycoengineered monoclonal antibody that binds to CD20 (a protein found only on B cells), is designed to attack and destroy targeted B cells directly and together with the immune system. It is currently approved in more than 50 countries in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia. In October the US FDA accepted for priority review Roche’s supplemental Biologic License Application for Gazyva in the treatment of patients with follicular lymphoma who relapsed after or are refractory to a rituximab-containing regimen, based on results of the phase III GADOLIN study.
Venetoclax is a small-molecule Bcl-2 inhibitor designed to interfere with a process some cancer cells use to survive, thereby promoting programmed cell death, or apoptosis. Ongoing phase II and III studies are investigating venetoclax alone and in combination with other medicines in certain types of chronic lymphocytic leukaemia (CLL), non-Hodgkin’s lymphoma, acute myelogenous leukaemia and multiple myeloma. Earlier this year the US FDA awarded breakthrough designation for venetoclax in the treatment of relapsed or refractory CLL with 17p deletion. Roche’s partner AbbVie has completed a submission to the US FDA for approval of venetoclax, based on the results of a positive phase II trial; AbbVie also plans to submit these data to the EMA and other regulatory authorities around the world for approval consideration.

Lebrikizumab is a first-in-class anti-IL-13 monoclonal antibody under investigation for the treatment of severe uncontrolled asthma. Lebrikizumab has been shown in phase II studies to significantly reduce asthma exacerbation rates and improve lung function in patients with high levels of the biomarker periostin. Phase III trial results are expected in the first half of 2016, with global filings planned soon after. Roche is also investigating lebrikizumab as a potential treatment for other types of lung disease and atopic dermatitis.

ACE910 (factor IXa/X biMAb) is an investigational bispecific antibody specifically engineered to support the interaction between factors IXa and X and hence mimic factor VIII, a protein essential to blood clotting. It is being developed for use in people with haemophilia A, irrespective of inhibitor status. Following encouraging phase I results, Roche plans to initiate a phase III trial of ACE910 in patients with factor VIII inhibitors by the end of 2015, a phase III trial in patients without inhibitors in 2016, and a study in paediatric patients (0–12 years) in 2016.

Lampalizumab (anti-Factor D Fab) is a selective inhibitor of complement-mediated inflammation. It is potentially the first disease-modifying therapy for geographic atrophy (GA), an advanced form of age-related macular degeneration. There are currently no effective therapies approved for GA, a significant cause of irreversible vision loss and blindness in the elderly. A phase II study with lampalizumab was the first to show efficacy in reducing the progression of retinal cell death in GA. Patient recruitment for a phase III program is on track. In addition to efficacy and safety, the studies are assessing the prognostic and predictive roles of a complement factor I profile biomarker. Results are expected in 2017. The US FDA has granted fast-track status to lampalizumab for the treatment of GA secondary to age-related macular degeneration.

Participants at the event are also being briefed on Roche’s ongoing efficiency initiatives in areas such as clinical development, pharmaceutical production and commercialisation, part of the Group’s commitment to optimising use of resources. One result of these efforts has been a doubling of the number of projects in late-stage clinical development since 2010, with no increase in development spend.

Roche experts will also explain the challenges and opportunities of molecular information and its emerging role in drug development, diagnosis, patient selection and treatment monitoring. A key part of Roche’s R&D is directed towards developing new techniques and platforms that can exploit the wealth of molecular data now becoming available in clinical trials and real-world treatment settings. The aim is to use these increasingly detailed data in research and development to help select drug targets and develop new medicines. Molecular information will increasingly be used in routine clinical practice to match patients to the most appropriate treatment and monitor their progress on therapy.

Partners and collaborations
Cotellic (cobimetinib) is being developed in collaboration with Exelixis.
Zelboraf (vemurafenib) is developed in collaboration with Plexxikon, a member of the Daiichi Sankyo Group.
Alectinib (RG7853) is being developed in collaboration with Chugai, a member of the Roche Group.
Venetoclax (Bcl-2 inhibitor, GDC-0199, RG7601) is being developed in collaboration with AbbVie.
ACE910 (RG6013) is being co-developed with Chugai, a member of the Roche Group.